阿司咪唑_MSDS_用途_密度_阿司咪唑CAS号【68844-77-9】

Astemizole 是一个长效的二代抗组胺药物,是常用的抗过敏药物,是组胺H1 受体 (histamine H1-receptor) 的拮抗剂,IC50 值为 4 nM。Astemizole 同时还具有hERG K+通道的阻断活性,IC50 值为0.9 nM。Astemizole 还具有抗胆碱能和止痒作用。

点击显示

[ 描述 ]:

Astemizole 是一个长效的二代抗组胺药物,是常用的抗过敏药物,是组胺H1 受体 (histamine H1-receptor) 的拮抗剂,IC50 值为 4 nM。Astemizole 同时还具有hERG K+通道的阻断活性,IC50 值为0.9 nM。Astemizole 还具有抗胆碱能和止痒作用。

[ 相关类别 ]:

信号通路 >> 免疫及炎症 >> 组胺受体

研究领域 >> 炎症/免疫

信号通路 >> 跨膜转运 >> 钾通道

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 组胺受体

[参考文献]

[1]. Laduron PM, et al. In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole. Mol Pharmacol. 1982 Mar;21(2):294-300.

[2]. Richards DM, et al. Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1984 Jul;28(1):38-61.

[ 密度 ]:
1.2 g/cm3

[ 沸点 ]:
627.3ºC at 760 mmHg

[ 熔点 ]:
172.9ºC

[ 分子式 ]:
C₂₈H₃₁FN₄O

[ 分子量 ]:
458.57

[ 闪点 ]:
333.2ºC

[ 精确质量 ]:
458.24800

[ PSA ]:
42.32000

[ LogP ]:
5.36220

[ 外观性状 ]:
白色粉末

[ 折射率 ]:
1.623

[ 储存条件 ]:
通风低温干燥,与库房食品原料分开存放

[ 水溶解性 ]:
DMSO: >20mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DD8968000

CHEMICAL NAME :: Benzimidazole, 1-(p-fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)pi perid-4-yl)amino)-

CAS REGISTRY NUMBER :: 68844-77-9

LAST UPDATED :: 199703

DATA ITEMS CITED :: 14

MOLECULAR FORMULA :: C28-H31-F-N4-O

MOLECULAR WEIGHT :: 458.63

WISWESSER LINE NOTATION :: T56 BN DNJ B1R DF& CM- DT6NTJ A2R DO1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 5400 ug/kg

TOXIC EFFECTS :: Behavioral - general anesthetic Cardiac - EKG changes not diagnostic of specified effects Cardiac - pulse rate increase, without fall in BP

REFERENCE :: PECAE5 Pediatric Emergency Care. (Williams & Wilkins, 428 E. Preston St., Baltimore, MD 21202) V.1- 1985- Volume(issue)/page/year: 9,23,1993

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 4 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity)

REFERENCE :: HUTODJ Human Toxicology. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants., RG 21 2XS, UK) V.1- 1981- Volume(issue)/page/year: 5,43,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 4 mg/kg

TOXIC EFFECTS :: Behavioral - coma Cardiac - arrhythmias (including changes in conduction) Gastrointestinal - nausea or vomiting

REFERENCE :: BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 292,660,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 4 mg/kg

TOXIC EFFECTS :: Cardiac - change in rate

REFERENCE :: JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 31,121,1993

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2560 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 355 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,381,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 28200 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,381,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2560 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1928 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,239,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 35 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,239,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >320 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 21800 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,381,1983

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 933 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 220 mg/kg

SEX/DURATION :: female 1-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical

REFERENCE :: CBPCEE Comparative Biochemistry and Physiology, C: Pharmacology, Toxicology and Endocrinology. (Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.74- 1983- Volume(issue)/page/year: 114,123,1996

点击显示

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P305 + P351 + P338

[ 危害码 (欧洲) ]:
Xn: Harmful;

[ 风险声明 (欧洲) ]:
R22;R36/37/38

[ 安全声明 (欧洲) ]:
S26-S36

[ 危险品运输编码 ]:
UN 2811 6.1 / PGII

[ WGK德国 ]:
3

[ RTECS号 ]:
DD8968000

[ 海关编码 ]:
2933990090

阿司咪唑上游产品

阿司咪唑下游产品

化合物(I)和碘甲烷在乙醇中回流8h，环合得到化合物(Ⅱ)。再水解脱去酯基，得到化合物(Ⅲ)。用对甲氧基苯乙基溴进行N-烷基化，得化合物(Ⅳ)。再用对氟苄基溴烷基化，得阿司咪唑。

1. 1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮的制备

在反应瓶中加入2-羟基苯并咪唑5.0g(37.3mmol)和NaH 1.6g(53mmol)(NaH含量大约为80%,浸入矿物油中)的DMF 100ml的悬浮液.加毕.在60ºC.(最好有N2保护)搅拌反应1h.再加入4-氟苄基氯(FBC)5.4g(37mmol),加热(60ºC)搅拌反应5.5h.冷却至室温后加入冰水700ml,用二氯甲烷(500ml×2)提取.有机层用食盐水洗.无水Na2SO4干燥.过滤.滤液减压浓缩.剩余物用石油醚析晶.得1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮固体8.0g,为无色结晶mp178~179ºC,收率88%.

2. 1-[(4-氟苯基)甲基]-2-氯苯并咪唑的制备

在反应瓶中加入1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮5.0g(20mmol)和POCl3 28ml(300mmol),搅拌加热回流5.5h.蒸除过量的POCl3,往剩余物加入冷水600ml,用稀氨水(即NH4OH)调至碱性,析出沉淀,过滤收集,用石油醚/二氯甲烷(2:1)重结晶,得无色结晶1-[(4-氟苯基)甲基]-2-氯苯并咪唑4.4g,收率84%,mp75~76ºC.

3. 4-[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯的制备

在反应瓶中加入1-[(4-氟苯基)甲基]-2-氯苯并咪唑3.32g(12.7mmol)和4-氨基-1-哌啶羧酸乙酯4.2g(26.4mmol),在氩气保护下搅拌升温至125 ºC,在该温度搅拌反应5h.冷却后加入10%NaOH水溶液60ml ,混合物用二氯甲烷提取,有机层用食盐水洗,无水Na2SO4干燥,过滤,滤液浓缩至干(减压下),剩余固体用闪式(快速)色谱法提纯,以二氯甲烷洗脱(固体粗品也用二氯甲烷调配进柱) ,得到固体用二氯甲烷/二异丙醚(2:1)重结晶,得4[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯无色结晶2.82g,收率56%,mp179~180ºC.

4. 1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐的制备

在反应瓶中加入4-[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯2.1g(5.3mmol)和48%氢溴酸130ml,强烈搅拌下加热,搅拌回流1h.真空下蒸除过量的氢溴酸,剩余物用2-丙醇结晶,得1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐2.5g,收率95%,mp280 ºC.

5. 阿司咪唑的合成

在反应瓶中加入1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐4.86g(10mmol)、NaH1.2g(80%含量#浸入矿物油中)和KI1.7g(10mmol)悬浮于DMF100ml的悬浮液,搅拌升温至70 ºC(在氩气保护下),在该温度下搅拌反应10h,然后加入4-甲氧基苯乙基氯1.71g(10mmol),连续搅拌加热(60~70 ºC)反应2h.冷却后,加入10%NaOH水溶液100ml,产生沉淀,过滤,用二异丙醚重结晶得阿司咪唑2.3g,收率50%,

点击显示

[ 海关编码 ]: 2933990090

[ 中文概述 ]:
2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Antihistamines modulate the integrin signaling pathway in h9c2 rat cardiomyocytes: Possible association with cardiotoxicity.

Hum. Exp. Toxicol. 34 , 796-807, (2015)

The identification of biomarkers for toxicity prediction is crucial for drug development and safety evaluation. The selective and specific biomarkers for antihistamines-induced cardiotoxicity is not w...

Tuning of EAG K(+) channel inactivation: molecular determinants of amplification by mutations and a small molecule.

J. Gen. Physiol. 140(3) , 307-24, (2012)

Ether-à-go-go (EAG) and EAG-related gene (ERG) K(+) channels are close homologues but differ markedly in their gating properties. ERG1 channels are characterized by rapid and extensive C-type inactiva...

Astemizole: a long-acting, nonsedating antihistamine.

Drug Intell. Clin. Pharm. 21(12) , 947-53, (1987)

Astemizole is a long-acting, highly selective histamine1-receptor antagonist with minimal central and anticholinergic effects. Comparison studies have shown astemizole to be equal or superior to curre...

更多文献